A novel phenotype‐based drug‐induced liver injury causality assessment tool ( <scp>DILI‐CAT</scp> ) allows for signal confirmation in early drug development-Reference-Cited by-同舟云学术

A novel phenotype‐based drug‐induced liver injury causality assessment tool ( DILI‐CAT ) allows for signal confirmation in early drug development

Author:

Hermann Richard P.¹,Rockey Don C.²^ORCID,Suzuki Ayako³⁴,Merz Michael⁵,Tillmann Hans L.⁶⁷^ORCID

Affiliation:

1. AstraZeneca Gaithersburg Maryland USA

2. Digestive Disease Research Center Medical University South Carolina Charleston South Carolina USA

3. Duke University Medical Center Durham North Carolina USA

4. Durham VA Medical Center Durham North Carolina USA

5. AstraZeneca Freiburg Germany

6. Division of Gastroenterology, Hepatology & Nutrition East Carolina University Greenville North Carolina USA

7. Greenville VA Health Care Center Greenville North Carolina USA

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

Reference26 articles.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献